Increasing the Dose of Busulfan Results in Lower Relapse Rates and Higher Non-Relapse Mortality in Patients With MDS/AML Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation  by Chen, Y.-B. et al.
Oral PresentationsALLOGENEIC TRANSPLANTS7
THE INCIDENCE AND NATURAL HISTORY OF PURE RED CELL APLASIA
IN MAJOR ABO MISMATCHED HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION IN PATIENTS RECEIVING MODERN REDUCE INTENSITY AND
REDUCED TOXICITY REGIMENS
Aung, F.M.1, Lichtiger, B.1, Alousi, A.2, Hosing, C.2, Qazilbash, M.2,
de Lima, M.2, Kebriaei, P.2, Khouri, I.2, Champlin, R.C.2, Popat, U.2
1University of Texas MD Anderson Cancer Center, Houston, TX;
2University of Texas MD Anderson Cancer Center, Houston, TX
Background: Major ABO matching in Hematopoietic stem cell
transplantation (HSCT) is not considered a contraindication to Al-
logeneic HSCT transplantation. Modern reduced intensity condi-
tioning regimens, and reduced toxicity regimens like busulfan and
fludarabine cause much less myeloablation than conventional mye-
loablative regimens like cyclophosphamide with busulfan or TBI.
Therefore recipient cells producing donor red cell specific antibody
are more likely to survive after a major ABO mismatched transplant
and cause red cell aplasia.We hypothesized that there is an increased
incidence of PRCA in Allogeneic HSCT patients who receive re-
duced intensity and reduced toxicity conditioning for stem cell trans-
plantation. The purpose of this study is to estimate the incidence and
describe the natural history of PRCA after HSCT.
Patients andMethods:AllMajor ABOmismatched Allogeneic He-
matopoietic stem cell transplants during a 2-year period (2007-2008)
were prospectively analyzed. PRCA was defined as lack of erythroid
precursors on bone marrow examination 30 days post-transplant,
lack of appearance of donor cells on Forward red cell Typing and be-
ing RBC transfusion dependent.
Results: Between 2007 and 2008, 596 patients underwent reduce in-
tensity Allogeneic HSCT transplants. TheHematopoietic stem cells
wereMajor ABO incompatible in 155(26%). Twelve (7.7%) patients
fulfilled the criteria for PRCA with 6 males/ 6 females and a median
age 51 years (range 24-73). The diagnoses were as follows: AML/
MDS (8), CML/MPD (2), ALL (1), Myeloma (1). The conditioning
regimen was [Fludarabine/Busulfan/ATG (9), Fludarabine/Bulsul-
fan (3), Fludarabine/Melphalan (2) and Fludarabine/Melphalan/
ATG (1). At day 30 chimerism studies showed a median of 90% do-
nor hemopoiesis in T lineage (range 21-100%)and amedian of 100%
(range 99-100%) in myeloid lineage Recovery of erythropoiesis was
noted in 10 patient with a median of 257 days (range 87-364) afterTable 1. Pre-and Post Transplant Data
Pre-Transplant Post-Transplant
Median (Range) Median (Range) Normal Range
Serum Total Bilirubin 0.5 (0.2-1.3) 0.7 (0.1-1.0) 0.0-1.0 mg/dl
Lactate Dehydrogenase 471 (212-2145) 1007 (349-1431) 313-618 IU/L
Alkaline Phosphatase 55 (36-140) 84 (69-238) 38-126 IU/L
Alanine
Aminotransferase
15 (11-54) 26 (12-305) 7-56 IU/L
Hemoglobin 8.4 (7.9-13.7) 11.3 (6.6-13.9) 14.0-18.0 g/dl
Serum Ferritin 1172 (81-3307) 4134 (1437-11634)* 22-322 ng/ml
Liver iron
Concentration
for 6/8 surviving
PRCA patients
15.8 mcg of iron
(12.5- 25 mcg/dry
liver weight)
RBCs Transfused Av 41 (15-131 units)
RBCs Transfusion
Dependence
265 (97-439 days)
Median Follow-up 22 (3-44 months)
*Post-transplant serum ferritin was not obtained on 1 patienttransplant. Four (33%) patients died (1 from disease recurrence
and 3 from transplant related mortality). Two of the patient who
died did not achieve red cell recovery. All the patients had significant
rbc transfusion requirement and developed iron overloadwith signif-
icant elevation of transaminases due to iron deposition in liver.
Conclusion: PRCA frequently (7.7%) occurs with current condi-
tioning regimens necessitating red cell transfusions for manymonths
after transplant resulting in significant iron overload.8
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Reduced intensity conditioning (RIC) regimens have allowed
many patients who would not have tolerated myeloablative condi-
tioning (MAC) to undergo allogeneic hematopoietic stem cell trans-
plantation (HSCT). Even so, dose intensity in RIC regimens vary
andmay affect treatment outcomes. In this analysis, we asked if a dif-
ference in intravenous busulfan dosing (3.2 mg/kg vs. 6.4 mg/kg) in
a fludarabine/busulfan (Flu/Bu) RIC regimen would affect HSCT
outcomes. A total of 188 patients with MDS or AML underwent
Flu/Bu RIC HSCT from matched related (MRD) or matched unre-
lated donors (MUD) at two partner institutions between 2004 and
2008. 118 patients received Bu1 (busulfan 0.8mg/kg/d 4with daily
fludarabine) while 70 patients received Bu2 (busulfan 1.6 mg/kg/d in
divided doses daily  4 with daily fludarabine). Patients had similar
clinical characteristics, including disease risk status, except that pa-
tients receiving Bu1 were younger (median age 58 vs 62, p 5
.0006), received more sirolimus based GVHD prophylaxis regimens
(88% vs 26%, p\ .0001), and had longer follow-up (median, Bu1
39.1months vs Bu2 18.3months, p\ .0001). The choice of RIC reg-
imens was based on institutional standard, enrollment on specific
protocols, and physician preference. The incidence of grades II-IV
acute GVHD (Bu1 19% vs Bu2 17%, p 5 0.82) and chronic
GVHD (2-year cumulative incidence, Bu1 42% vs Bu2 32%, p 5
.07) were similar. Patients who received Bu1 had lower rates of
non-relapse mortality (NRM) at 1-year (Bu1 2% vs Bu2 9%) and
2-years (Bu1 4%vs Bu2 11%, p5 0.013). Cumulative rates of relapse
at 1-year (Bu1 59% vs Bu2 49%) and 2-years (Bu1 68% vs Bu2 49%,
p 5 .022) were significantly higher in patients receiving Bu1.
Table 1. Cumulative Incidences of NRM and Relapse
Bu1 Bu2 p-value1-year NRM 1.7% 8.6%
2-year NRM 3.7% 11.1% 0.013
1-year Relapse 59.3% 48.6%
2-year Relapse 68.1% 48.6% 0.022Progression-free survival at 1-year (Bu1 39% vs Bu2 43%) and 2-
years (Bu1 28% vs Bu2 40%, p 5 .20) was similar between the two
groups. Overall survival at 1-year (Bu1 52% vs Bu2 61%) and 2-years
(Bu1 39% vs Bu2 50%, p 5 .22) was also similar. In patients with
MDS/AML undergoing Flu/Bu RIC SCT, Bu2 appears to have sig-
nificantly lower rates of disease relapse, yet higher rates of NRM.
Longer follow-up is needed to confirm if these differences are dura-
ble and if there are specific risk groups which would benefit more
from the increased intensity of RIC.S153
